Business Description
Teva Pharmaceutical Industries Ltd
NAICS : 325412
ISIN : IL0062905489
Share Class Description:
TEVVF.PFD: 7 % Conv.Cum.Pfd Shs Mandatory Conv. 15.12.2018Compare
Compare
Traded in other countries / regions
TEVA.USATEVA.Israel0LER.UKTEV.GermanyTEVA.MexicoTEVA.AustriaT1EV34.Brazil IPO Date
2015-12-02Description
Teva Pharmaceutical Industries, based in Israel, is the leading generic drug manufacturer in the world. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the U.S. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in three main therapeutic areas: central nervous system with Copaxone, Ajovy, and Austedo; respiratory with Qvar and ProAir; and oncology with Truxima, Herzuma, and Bendeka/Treanda. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a U.S.-based generic and specialty drug distributor.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.16 | |||||
| Equity-to-Asset | 0.17 | |||||
| Debt-to-Equity | 2.69 | |||||
| Debt-to-EBITDA | 12.94 | |||||
| Interest Coverage | 3.1 | |||||
| Piotroski F-Score | 5/9 | |||||
| Altman Z-Score | 0.21 | |||||
| Beneish M-Score | -2.47 | |||||
| WACC vs ROIC | ||||||
Growth Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -2.4 | |||||
| 3-Year EPS without NRI Growth Rate | -0.1 | |||||
| 3-Year FCF Growth Rate | 8.9 | |||||
| 3-Year Book Growth Rate | -9.9 | |||||
| Future 3-5Y Total Revenue Growth Rate | 1 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 6-1 Month Momentum % | -4.94 | |||||
| 12-1 Month Momentum % | 20.15 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.02 | |||||
| Quick Ratio | 0.69 | |||||
| Cash Ratio | 0.26 | |||||
| Days Inventory | 179.18 | |||||
| Days Sales Outstanding | 80.45 | |||||
| Days Payable | 103.76 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 4.93 | |||||
| 5-Year Yield-on-Cost % | 4.93 | |||||
| 3-Year Average Share Buyback Ratio | -0.7 | |||||
| Shareholder Yield % | 10.98 |
Profitability Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 48.24 | |||||
| Operating Margin % | 20.14 | |||||
| Net Margin % | -3.53 | |||||
| ROE % | -7.52 | |||||
| ROA % | -1.29 | |||||
| ROIC % | 8.33 | |||||
| ROC (Joel Greenblatt) % | 6.61 | |||||
| ROCE % | 1.28 | |||||
| Years of Profitability over Past 10-Year | 4 |
GF Value Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Forward PE Ratio | 5.43 | |||||
| PE Ratio without NRI | 5.07 | |||||
| PS Ratio | 0.92 | |||||
| PB Ratio | 1.93 | |||||
| Price-to-Free-Cash-Flow | 17.22 | |||||
| Price-to-Operating-Cash-Flow | 10.6 | |||||
| EV-to-EBIT | 77.68 | |||||
| EV-to-EBITDA | 20.19 | |||||
| EV-to-Revenue | 1.99 | |||||
| EV-to-FCF | 37.31 | |||||
| Earnings Yield (Greenblatt) % | 1.29 | |||||
| FCF Yield % | 5.73 | |||||
| Forward Rate of Return (Yacktman) % | 22.27 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with OTCPK:TEVVF.PFD
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Teva Pharmaceutical Industries Ltd Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | 0 | ||
| Beta | 0 | ||
| Volatility % | 37.57 | ||
| 14-Day RSI | 0 | ||
| 14-Day ATR ($) | 0 | ||
| 20-Day SMA ($) | 0 | ||
| 12-1 Month Momentum % | 20.15 | ||
| 52-Week Range ($) | 286.75 - 471 | ||
| Shares Outstanding (Mil) |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Teva Pharmaceutical Industries Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Teva Pharmaceutical Industries Ltd Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Teva Pharmaceutical Industries Ltd Frequently Asked Questions
What is Teva Pharmaceutical Industries Ltd(TEVVF.PFD)'s stock price today?
The current price of TEVVF.PFD is $355.00. The 52 week high of TEVVF.PFD is $471.00 and 52 week low is $286.75.
When is next earnings date of Teva Pharmaceutical Industries Ltd(TEVVF.PFD)?
The next earnings date of Teva Pharmaceutical Industries Ltd(TEVVF.PFD) is 2024-05-08.
Does Teva Pharmaceutical Industries Ltd(TEVVF.PFD) pay dividends? If so, how much?
The Dividend Yield %  of Teva Pharmaceutical Industries Ltd(TEVVF.PFD) is 4.93% (As of Today), Highest Dividend Payout Ratio of Teva Pharmaceutical Industries Ltd(TEVVF.PFD) was 0.27. The lowest was 0.21. And the median was 0.25. The  Forward Dividend Yield % of Teva Pharmaceutical Industries Ltd(TEVVF.PFD) is 0%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers